CliffBio
small molecule

ZEGERID

OMEPRAZOLE; SODIUM BICARBONATE

Loss of exclusivity—loss of exclusivity
CompanySalix Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameZEGERID
Active ingredientOMEPRAZOLE; SODIUM BICARBONATE
Strength40MG/PACKET;1.68GM/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formFOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2004
Marketing statusDISCN

More from Salix Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.